BioXcel Therapeutics (BTAI +2.6%)
initiates the second portion of its Phase 1b/2 clinical trial
evaluating BCXL701, combined with Merck’s Keytruda (pembrolizumab), in
patients with treatment-emergent neuroendocrine prostate cancer (an
aggressive form).
Preliminary data should be available in Q4.
The company says small molecule BXCL701 is
designed to stimulate both the innate and acquired immune systems by
inhibiting an enzyme called dipeptidyl peptidase (DPP) 8/9 and blocking
immune invasion by targeting fibroblast activation protein (FAP).
https://seekingalpha.com/news/3565310-bioxcel-launches-phase-2-study-of-bxcl701-in-aggressive-type-of-prostate-cancer
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.